Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company ...

We recently compiled a list of the 11 AI News You Should Not Miss. In this article, we are going to take a look at where ...

Roth MKM analyst Matt Koranda raised the firm’s price target on Byrna Technologies (BYRN) to $23 from $22 and keeps a Buy ...

Fintel reports that on December 11, 2024, Roth MKM initiated coverage of Powell Industries (NasdaqGS:POWL) with a Buy ...

Roth MKM analyst Mike Niehuser maintained a Buy rating on Solitario Exploration & Royalty (XPL – Research Report) yesterday and set a price ...

Roth MKM last night initiated coverage of Powell (POWL) with a Buy rating and $312 price target The firm believes a higher than historical ...

Yext (NYSE:YEXT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Roth Mkm in a report released on Tuesday,Benzinga reports. They presently have a $10.50 target ...

Analysts at Roth Capital issued their Q1 2026 EPS estimates for shares of Uranium Energy in a research report issued to clients and investors on Monday, December 9th. Roth Capital analyst J. Reagor ...

As of December 3, 2024, the average one-year price target for Longeveron is $8.67/share. The forecasts range from a low of $6.06 to a high of $10.50. The average price target represents an ...

Roth MKM analyst Boobalan Pachaiyappan last night initiated coverage of Gain Therapeutics (GANX) with a Buy rating and $7 price target The firm says GT-02287, a potential $4B drug that ...

On Friday, Roth/MKM initiated coverage on shares of CervoMed (NASDAQ:CRVO), a pharmaceutical company, with a Buy rating and a 12-month price target of $45.00. The firm's positive outlook is based ...

On Friday, Roth/MKM initiated coverage on shares of CervoMed (NASDAQ:CRVO), a pharmaceutical company, with a Buy rating and a 12-month price target of $45.00. The firm's positive outlook is based on a ...